Survodutide SYNCHRONIZE-1: what the phase 3 data actually shows
The once-weekly glucagon/GLP-1 dual agonist reduced body weight by up to 13.0% at 76 weeks — real and clinically meaningful, but below the phase 2 headline and below tirzepatide. Here's the honest read of the numbers.
How It Works
Survodutide activates BOTH the GLP-1 receptor (appetite, satiety, glucose control) and the glucagon receptor. Layering glucagon agonism on top of GLP-1 is the design bet behind its weight-loss and liver-fat effects.
Unlike pure GLP-1 drugs, the glucagon arm is intended to raise energy expenditure and drive hepatic fat oxidation — the mechanistic basis for survodutide’s strong MASH / liver-fat signal.
Subcutaneous once-weekly, escalated up to 3.6 mg or 6.0 mg. Slow titration is required because gastrointestinal side effects are the main tolerability limit.
SYNCHRONIZE-1’s primary number uses the conservative treatment-regimen estimand, which counts early discontinuations and rescue-medication use — so it reads lower than phase 2’s on-treatment figures.
What the Data Shows
Key Takeaways
- SYNCHRONIZE-1 (n=725) met both primary endpoints: mean weight change at week 76 was -12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% for placebo (treatment-regimen estimand).
- 72.6% (3.6 mg) and 71.9% (6.0 mg) of participants lost at least 5% of body weight vs 46.3% on placebo (P<0.001 for all comparisons).
- The 3.6 mg and 6.0 mg doses produced almost identical weight loss — going higher added little, largely because gastrointestinal tolerability caps the achievable dose.
- In the separate SYNCHRONIZE-MASLD phase 3 trial, 84.2% of survodutide-treated patients had a ≥30% reduction in liver fat vs 24.3% on placebo — the glucagon arm gives a real liver advantage over pure GLP-1 drugs.
- Phase 2 MASH data showed histologic MASH improvement without worsening fibrosis in up to 62% of patients (4.8 mg) vs 14% on placebo.
- Gastrointestinal side effects dominate the safety profile: reported by 80.9% (3.6 mg) and 89.7% (6.0 mg) of participants, typically mild-to-moderate; no deaths were reported.
- Whether survodutide is more or less effective than tirzepatide — cross-trial numbers (~13% vs ~21%) are indirect and no head-to-head trial has been run.
- How it performs in people with type 2 diabetes — SYNCHRONIZE-1 excluded diabetes; that population is studied separately in SYNCHRONIZE-2.
- Long-term (multi-year) weight maintenance and hard cardiovascular outcomes — the SYNCHRONIZE cardiovascular outcomes trial is still ongoing.
- Which estimand best predicts real-world results — the on-treatment figures are higher than the ~13% headline, and the gap depends on how well a person tolerates the GI side effects.
- When or whether it will be approved or available — survodutide is investigational, not FDA/EMA-approved, and is not sold as a research chemical or by consumer vendors.
Frequently Asked Questions
What is survodutide and how does it work?
Survodutide (BI 456906) is an investigational once-weekly injectable that activates both the GLP-1 receptor and the glucagon receptor. GLP-1 activity suppresses appetite and improves glucose handling, while glucagon activity is intended to raise energy expenditure and reduce liver fat — a dual mechanism that pure GLP-1 drugs like semaglutide do not have.
What did the SYNCHRONIZE-1 phase 3 trial show?
In 725 adults with obesity and without diabetes, once-weekly survodutide reduced body weight by a mean of 12.2% (3.6 mg) to 13.0% (6.0 mg) at week 76 versus 5.4% on placebo (treatment-regimen estimand). About 72% of participants on each dose lost at least 5% of body weight versus 46% on placebo.
How does survodutide compare to tirzepatide (Mounjaro/Zepbound)?
No head-to-head trial exists. Indirectly, survodutide’s ~13% treatment-regimen weight loss at 76 weeks reads below tirzepatide’s ~20.9% at 15 mg in SURMOUNT-1, but the trials used different designs, doses and estimands, so the comparison is approximate. Survodutide’s distinguishing feature is its liver-fat benefit.
Why is survodutide considered promising for fatty liver (MASH/MASLD)?
Its glucagon arm drives hepatic fat oxidation. In the SYNCHRONIZE-MASLD phase 3 trial, 84.2% of treated patients had a ≥30% reduction in liver fat versus 24.3% on placebo, and phase 2 data showed histologic MASH improvement in up to 62% of patients — a signal stronger than typical GLP-1 monotherapy.
Is survodutide FDA-approved or available to buy?
No. Survodutide is investigational, developed by Boehringer Ingelheim and Zealand Pharma, and is in phase 3 trials. It is not approved by the FDA or EMA and is not legitimately available as a research chemical or from consumer vendors.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Survodutide is investigational and not approved by the FDA or EMA. Cross-trial comparisons are indirect. Consult a licensed clinician before making any treatment decisions.